CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
Imipramine Pamoatedrug
Likely dose
Imipramine Pamoate 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01107353
NCT01107353N/ACompleted
CompareCT.gov

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions

Roxane Laboratories·interventional·Posted Apr 20, 2010·Updated Feb 5, 2018

In Brief

A clinical study evaluating Imipramine Pamoate for Depression. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The objective of this study was to prove the bioequivalence of Imipramine Pamoate 75 mg Capsules under fasting conditions

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 20, 2010
Enrollment StartAug 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.2 years ago

Interventions

Imipramine Pamoatedrug

75 mg capsule